Evidence map›Paper›PMID 26586118›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2015

Clinical guideline seom: hereditary colorectal cancer.

C Guillén-Ponce, R Serrano, A B Sánchez-Heras, A Teulé, I Chirivella, T Martín, E Martínez, R Morales, L Robles

Open access · hybridAbstract read
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Guideline
  2. Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  3. Juvenile polyposis syndrome: A case report.Clinical case reports · 2023
    Article
  4. Article
  5. Review
  6. Article
  7. SEOM Guidelines 2015: a new era in the collaboration with the Spanish Cancer Research Cooperative Groups.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

C Guillén-PonceMedical Oncology Department, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo, KM 9,100, 28034, Madrid, Spain. carmenguillenponce@gmail.com.
R SerranoMedical Oncology Department, Hospital Reina Sofía, Córdoba, Spain.
A B Sánchez-HerasMedical Oncology Department, Hospital General Universitario de Elche, Elche (Alicante), Spain.
A TeuléMedical Oncology Department, Instituto Catalán de Oncología (ICO), Barcelona, Spain.
I ChirivellaMedical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
T MartínMedical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
E MartínezMedical Oncology Department, Hospital Marqués de Valdecilla, Santander, Spain.
R MoralesMedical Oncology Department, Hospital La Mancha Centro, Alcázar De San Juan (Ciudad Real), Spain.
L RoblesMedical Oncology Department, Hospital Doce de Octubre, Madrid, Spain.
Complejo Hospitalario de Salamanca · ESHospital Clínico Universitario de Valencia · ESHospital General Universitario de Elche · ESHospital Universitario 12 De Octubre · ESHospital Universitario Ramón y Cajal · ESHospital Universitario Reina Sofía · ESInstitut Català d'Ornitologia · ESMarqués de Valdecilla University Hospital · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic mutations have been identified as the cause of inherited cancer risk in some colon cancer; these mutations are estimated to account for only 5-6 % of colorectal cancer (CRC) cases overall. Up to 25-30 % of patients have a family history of CRC that suggests a hereditary component, common exposures among family members, or a combination of both. Cancers in people with a hereditary predisposition typically occur at an earlier age than in sporadic cases. A predisposition to CRC may include a predisposition to other cancers, such as endometrial cancer. We describe genetics, current diagnosis and management of CRC hereditary syndromes pointing to a multidisciplinary approach to achieve the best results in patients and family outcomes.

Indexed as

Genetic Predisposition to DiseaseAdolescentAdultChildChild, PreschoolColorectal Neoplasms, Hereditary NonpolyposisEarly Detection of CancerFemaleHumansInfantInfant, NewbornMaleMiddle AgedPractice Guidelines as TopicYoung AdultAdenomatous polyposisColon cancerHereditary colorectal cancerLynch syndrome

Identifiers

PMID26586118
PMCPMC4689750
OpenAlexW2240136024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.